GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » European Medical Solutions (FRA:AS0) » Definitions » Debt-to-Equity

European Medical Solutions (FRA:AS0) Debt-to-Equity : 1.81 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is European Medical Solutions Debt-to-Equity?

European Medical Solutions's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €6.06 Mil. European Medical Solutions's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €11.86 Mil. European Medical Solutions's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €9.89 Mil. European Medical Solutions's debt to equity for the quarter that ended in Dec. 2023 was 1.81.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for European Medical Solutions's Debt-to-Equity or its related term are showing as below:

FRA:AS0' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.93   Med: 0.03   Max: 1.81
Current: 1.81

During the past 12 years, the highest Debt-to-Equity Ratio of European Medical Solutions was 1.81. The lowest was -4.93. And the median was 0.03.

FRA:AS0's Debt-to-Equity is ranked worse than
93.49% of 1045 companies
in the Biotechnology industry
Industry Median: 0.14 vs FRA:AS0: 1.81

European Medical Solutions Debt-to-Equity Historical Data

The historical data trend for European Medical Solutions's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Medical Solutions Debt-to-Equity Chart

European Medical Solutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.17 -0.94 1.16 1.38 1.81

European Medical Solutions Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 1.18 1.38 1.58 1.81

Competitive Comparison of European Medical Solutions's Debt-to-Equity

For the Biotechnology subindustry, European Medical Solutions's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


European Medical Solutions's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, European Medical Solutions's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where European Medical Solutions's Debt-to-Equity falls into.



European Medical Solutions Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

European Medical Solutions's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

European Medical Solutions's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


European Medical Solutions  (FRA:AS0) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


European Medical Solutions Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of European Medical Solutions's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


European Medical Solutions Business Description

Traded in Other Exchanges
Address
7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

European Medical Solutions Headlines

No Headlines